Difficult Asthma: Unmet Needs and Future Directions

  • Shu-Yi Liao
  • Amir A. Zeki
  • Nizar JarjourEmail author
Part of the Respiratory Medicine book series (RM)


Despite advances in asthma management, many patients continue to suffer from uncontrolled asthma. In the United States alone, ten patients per day die from asthma, and for several decades, the prevalence and economic burden of asthma have been increasing. This has placed greater emphasis on the need to develop new therapeutic approaches to control asthma that are also cost-effective. Evidence indicates that asthma is a heterogeneous disease; therefore, a “one-size-fits-all” approach may not be effective in all patients. The availability of new anti-IL5 biologics has made a significant progress in treating severe eosinophilic asthma (type 2); however, no such therapies have been developed to target non-eosinophilic asthma (non-type 2). In addition, a subset of these type 2 asthma patients continues to have exacerbations despite treatments targeting IL5. Therefore, there is a significant unmet need for identifying different asthma phenotypes and developing precision medicine therapies targeting each phenotype to improve patient outcomes. One such approach could be based on an “omics” diagnostic panel to stratify patients’ molecular phenotypes and consider targeted treatments based on these phenotypes. Additional approaches to optimize asthma control include developing novel therapeutics, new technologies to aid in asthma management, and more effective and safer drug delivery systems.


Asthma Unmet need -omics Phenotype Biologics 


  1. 1.
    Prevention CfDCa. Uncontrolled asthma among persons with current asthma. 2014.
  2. 2.
    Sullivan PW, Slejko JF, Ghushchyan VH, Sucher B, Globe DR, Lin SL, et al. The relationship between asthma, asthma control and economic outcomes in the United States. J Asthma. 2014;51(7):769–78. Scholar
  3. 3.
    Nunes C, Pereira AM, Morais-Almeida M. Asthma costs and social impact. Asthma Res Pract. 2017;3:1. Scholar
  4. 4.
    Loftus PA, Wise SK. Epidemiology and economic burden of asthma. Int Forum Allergy Rhinol. 2015;5(Suppl 1):S7–10. Scholar
  5. 5.
    Nurmagambetov T, Kuwahara R, Garbe P. The economic burden of asthma in the United States, 2008–2013. Ann Am Thorac Soc. 2018;15(3):348–56. Scholar
  6. 6.
    European lung white book. Brussels: European Respiratory Society and the European Lung Foundation; 2003.Google Scholar
  7. 7.
    Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–73. Scholar
  8. 8.
    Carr TF, Zeki AA, Kraft M. Eosinophilic and noneosinophilic asthma. Am J Respir Crit Care Med. 2018;197(1):22–37. Scholar
  9. 9.
    McGrath KW, Icitovic N, Boushey HA, Lazarus SC, Sutherland ER, Chinchilli VM, et al. A large subgroup of mild-to-moderate asthma is persistently noneosinophilic. Am J Respir Crit Care Med. 2012;185(6):612–9. Scholar
  10. 10.
    Chapman KR, Walker L, Cluley S, Fabbri L. Improving patient compliance with asthma therapy. Respir Med. 2000;94(1):2–9. Scholar
  11. 11.
    Canonica GW, Baena-Cagnani CE, Blaiss MS, Dahl R, Kaliner MA, Valovirta EJ, et al. Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy. 2007;62(6):668–74. Scholar
  12. 12.
    Keet CA, McCormack MC, Pollack CE, Peng RD, McGowan E, Matsui EC. Neighborhood poverty, urban residence, race/ethnicity, and asthma: rethinking the inner-city asthma epidemic. J Allergy Clin Immunol. 2015;135(3):655–62. Scholar
  13. 13.
    Akinbami LJ, Moorman JE, Bailey C, Zahran HS, King M, Johnson CA, et al. Trends in asthma prevalence, health care use, and mortality in the United States, 2001–2010. NCHS Data Brief. 2012;(94):1–8.Google Scholar
  14. 14.
    Gauthier M, Ray A, Wenzel SE. Evolving concepts of asthma. Am J Respir Crit Care Med. 2015;192(6):660–8. Scholar
  15. 15.
    Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–93. Scholar
  16. 16.
    de Groot JC, Ten Brinke A, Bel EH. Management of the patient with eosinophilic asthma: a new era begins. ERJ Open Res. 2015;1(1):00024-2015. Scholar
  17. 17.
    Hasegawa K, Stoll SJ, Ahn J, Bittner JC, Camargo CA Jr. Prevalence of eosinophilia in hospitalized patients with asthma exacerbation. Respir Med. 2015;109(9):1230–2. Scholar
  18. 18.
    Bender BG, Bender SE. Patient-identified barriers to asthma treatment adherence: responses to interviews, focus groups, and questionnaires. Immunol Allergy Clin N Am. 2005;25(1):107–30. Scholar
  19. 19.
    Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med. 1994;149(2 Pt 2):S69–76; discussion S7–8. Scholar
  20. 20.
    NHLBI. Guidelines for the diagnosis and management of asthma (EPR-3) In: Services DoHaH, editor.: National Asthma Education and Prevention Program Coordinating Committee; 2007.Google Scholar
  21. 21.
    Pool AC, Kraschnewski JL, Poger JM, Smyth J, Stuckey HL, Craig TJ, et al. Impact of online patient reminders to improve asthma care: a randomized controlled trial. PLoS One. 2017;12(2):e0170447. Scholar
  22. 22.
    Christopher PP, Garcia-Sampson LG, Stein M, Johnson J, Rich J, Lidz C. Enrolling in clinical research while incarcerated: what influences participants’ decisions? Hast Cent Rep. 2017;47(2):21–9. Scholar
  23. 23.
    Rios D, Magasi S, Novak C, Harniss M. Conducting accessible research: including people with disabilities in public health, epidemiological, and outcomes studies. Am J Public Health. 2016;106(12):2137–44. Scholar
  24. 24.
    Zeki AA, Khaleel HR. Respiratory telemedicine. In: Khaleel HR, editor. Telemedicine: emerging technologies, applications, and impact on health care outcomes. New York: Nova Science Publishers; 2015.Google Scholar
  25. 25.
    Lewis N. Telehealth helps close health care disparity gap in rural areas. AAMCNews. 2016.
  26. 26.
    Swedin L, Saarne T, Rehnberg M, Glader P, Niedzielska M, Johansson G, et al. Patient stratification and the unmet need in asthma. Pharmacol Ther. 2017;169:13–34. Scholar
  27. 27.
    Barnes PJ. Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap syndromes. J Allergy Clin Immunol. 2015;136(3):531–45. Scholar
  28. 28.
    Wurst KE, St Laurent S, Hinds D, Davis KJ. Disease burden of patients with asthma/COPD overlap in a US claims database: impact of ICD-9 coding-based definitions. COPD. 2017;14(2):200–9. Scholar
  29. 29.
    GINA/GOLD. Asthma, COPD, and asthma-COPD overlap syndrome (ACOS). Global initiative for asthma. 2017.
  30. 30.
    Bonnelykke K, Sleiman P, Nielsen K, Kreiner-Moller E, Mercader JM, Belgrave D, et al. A genome-wide association study identifies CDHR3 as a susceptibility locus for early childhood asthma with severe exacerbations. Nat Genet. 2014;46(1):51–5. Scholar
  31. 31.
    Himes BE, Jiang X, Hu R, Wu AC, Lasky-Su JA, Klanderman BJ, et al. Genome-wide association analysis in asthma subjects identifies SPATS2L as a novel bronchodilator response gene. PLoS Genet. 2012;8(7):e1002824. Scholar
  32. 32.
    Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N Engl J Med. 2011;365(13):1173–83. Scholar
  33. 33.
    Modena BD, Bleecker ER, Busse WW, Erzurum SC, Gaston BM, Jarjour NN, et al. Gene expression correlated with severe asthma characteristics reveals heterogeneous mechanisms of severe disease. Am J Respir Crit Care Med. 2017;195(11):1449–63. Scholar
  34. 34.
    Bigler J, Boedigheimer M, Schofield JPR, Skipp PJ, Corfield J, Rowe A, et al. A severe asthma disease signature from gene expression profiling of peripheral blood from U-BIOPRED cohorts. Am J Respir Crit Care Med. 2017;195(10):1311–20. Scholar
  35. 35.
    Lefaudeux D, De Meulder B, Loza MJ, Peffer N, Rowe A, Baribaud F, et al. U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol. 2017;139(6):1797–807. Scholar
  36. 36.
    Scelfo C, Galeone C, Bertolini F, Caminati M, Ruggiero P, Facciolongo N, et al. Towards precision medicine: the application of omics technologies in asthma management. F1000Res. 2018;7:423. Scholar
  37. 37.
    Hamsten C, Haggmark A, Grundstrom J, Mikus M, Lindskog C, Konradsen JR, et al. Protein profiles of CCL5, HPGDS, and NPSR1 in plasma reveal association with childhood asthma. Allergy. 2016;71(9):1357–61. Scholar
  38. 38.
    Brennan L. Metabolomics in nutrition research: current status and perspectives. Biochem Soc Trans. 2013;41(2):670–3. Scholar
  39. 39.
    Hao K, Bosse Y, Nickle DC, Pare PD, Postma DS, Laviolette M, et al. Lung eQTLs to help reveal the molecular underpinnings of asthma. PLoS Genet. 2012;8(11):e1003029. Scholar
  40. 40.
    Amur S, LaVange L, Zineh I, Buckman-Garner S, Woodcock J. Biomarker qualification: toward a multiple stakeholder framework for biomarker development, regulatory acceptance, and utilization. Clin Pharmacol Ther. 2015;98(1):34–46. Scholar
  41. 41.
    Chiappori A, De Ferrari L, Folli C, Mauri P, Riccio AM, Canonica GW. Biomarkers and severe asthma: a critical appraisal. Clin Mol Allergy. 2015;13:20. Scholar
  42. 42.
    Huffaker MF, Carchia M, Harris BU, Kethman WC, Murphy TE, Sakarovitch CCD, et al. Passive nocturnal physiologic monitoring enables early detection of exacerbations in children with asthma. A proof-of-concept study. Am J Respir Crit Care Med. 2018;198(3):320–8. Scholar
  43. 43.
    Hoch H, Kempe A, Brinton J, Szefler S. Feasibility of medication monitoring sensors in high risk asthmatic children. J Asthma. 2018:1–3. Scholar
  44. 44.
    Chan AH, Reddel HK, Apter A, Eakin M, Riekert K, Foster JM. Adherence monitoring and e-health: how clinicians and researchers can use technology to promote inhaler adherence for asthma. J Allergy Clin Immunol Pract. 2013;1(5):446–54. Scholar
  45. 45.
    Wong-McGrath K, Denlinger LC, Bleecker ER, Castro M, Gaston B, Israel E, et al. Internet-based monitoring in the severe asthma research program identifies a subgroup of patients with labile asthma control. Chest. 2018;153(2):378–86. Scholar
  46. 46.
    Messinger AI, Deterding RR, Szefler SJ. Bringing technology to day-to-day asthma management. Am J Respir Crit Care Med. 2018;198(3):291–2. Scholar
  47. 47.
    Wu AC, Carpenter JF, Himes BE. Mobile health applications for asthma. J Allergy Clin Immunol Pract. 2015;3(3):446–8 e1-16. Scholar
  48. 48.
    Andrianasolo RM, Kesse-Guyot E, Adjibade M, Hercberg S, Galan P, Varraso R. Associations between dietary scores with asthma symptoms and asthma control in adults. Eur Respir J. 2018;52(1):1702572. Scholar
  49. 49.
    Guilleminault L, Williams EJ, Scott HA, Berthon BS, Jensen M, Wood LG. Diet and asthma: is it time to adapt our message? Nutrients. 2017;9(11):1227. Scholar
  50. 50.
    Li Q, Baines KJ, Gibson PG, Wood LG. Changes in expression of genes regulating airway inflammation following a high-fat mixed meal in asthmatics. Nutrients. 2016;8(1):30. Scholar
  51. 51.
    Ilmarinen P, Tuomisto LE, Niemela O, Danielsson J, Haanpaa J, Kankaanranta T, et al. Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma. Eur Respir J. 2016;48(4):1052–62. Scholar
  52. 52.
    Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195–207. Scholar
  53. 53.
    Peters MC, McGrath KW, Hawkins GA, Hastie AT, Levy BD, Israel E, et al. Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med. 2016;4(7):574–84. Scholar
  54. 54.
    Esty B, Bartnikas LM, Charbonnier LM, Massoud AH, Leon-Astudillo C, Visner G, et al. Anti-IL-6 treatment in two pediatric patients with severe persistent asthma with the IL4R576variant. J Allergy Clin Immunol. 2018;141(2):AB109. Scholar
  55. 55.
    Chung KF. Tralokinumab unsuccessful for management of severe, uncontrolled asthma. Lancet Respir Med. 2018;6(7):480–1. Scholar
  56. 56.
    Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016;4(10):781–96. Scholar
  57. 57.
    Holguin F. Biological treatments for eosinophilic asthma enter the airways. Am J Respir Crit Care Med. 2018;198(5):551–2. Scholar
  58. 58.
    Lightwood D, Tservistas M, Zehentleitner M, Sarkar K, Turner A, Bracher M, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med. 2018;198(5):610–9. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Division of Pulmonary, Critical Care, and Sleep MedicineUniversity of California DavisSacramentoUSA
  2. 2.Division of Allergy, Pulmonary and Critical Care MedicineUniversity of WisconsinMadisonUSA

Personalised recommendations